Sunshine Heart is a medical device company focused on commercializing C-Pulse™—an implantable, non-blood-contacting heart assist therapy for treating people with moderate heart failure: a condition in which the heart progressively loses its ability to efficiently pump blood throughout the body.  C-Pulse reduces the symptoms of heart failure through the use of counterpulsation technology, which enables an increase in cardiac output and coronary blood flow and a reduction in the heart’s pumping workload.  Sunshine Heart currently has an IDE application under consideration by the FDA seeking approval to conduct a US clinical trial with C-Pulse.  In this episode, Sunshine Heart’s CEO Don Rohrbaugh discusses early heart-failure intervention.